Simon Agwale, Ph. D is the CEO of Innovative Biotech, Nigeria and Innovative Biotech USA Inc. Dr Agwale is the Vice Chair of AVMI’s Board of Directors and the lead of the Vaccine Technology working group. He was the lead and member of the Africa CDC-PAVM’s Technology Transfer and IP bold program and Talent Development workstreams respectively.

Dr. Agwale has a vision for the development and investigation of HIV vaccine constructs from prevalent Nigerian strains which are relevant to Nigerians. He is also currently developing novel vaccines against Covid-19, Ebola, HPV, and HIV using innovative viral-like particles (VLPs), and has recently licensed several technologies, which he is in the process of further developing and commercializing. Through INNOVATIVE, Dr. Agwale is striving to further develop and refine these dynamic, novel treatments, and in doing so, expand domestic vaccine manufacturing capabilities in Nigeria to serve the African community.

Dr. Agwale was a Postdoc fellow at the Institute of Human Virology Baltimore, USA and Visiting Scientist at various institutions in Brazil, Germany, UK including the US Vaccine Research Center/NIH, and US Center for Disease Control and prevention in Atlanta. Dr. Agwale was West Africa's representative on HIV/AIDS for Developing countries Coordinating Committee (DCCC) at European and Developing Countries Clinical Trials Programme, where he was also the chair of the African Scientists committee (DCCC). He is a recipient of several scholarships, fellowships and grants from reputable organizations around the world. He has also authored and co-authored numerous noteworthy publications.